ArticleMolecular biology reports2014
RSPO fusion transcripts in colorectal cancer in Japanese population.
Article in Molecular biology reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 59 citations in OpenAlex.
- Article
- Hierarchical clustering defines hypermethylated RSPO2 as early-stage potential biomarker in colorectal cancer.Global medical genetics · 2025Article
- Article
- RSPO2 as Wnt signaling enabler: Important roles in cancer development and therapeutic opportunities.Genes & diseases · 2024Review
- Nab-Paclitaxel and Gemcitabine as First-Line Treatment of Metastatic Ampullary Adenocarcinoma with a NovelBiomedicines · 2023Article
- R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer.The Journal of pathology · 2022Article
- Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer.British journal of cancer · 2022Article
- Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition.Pharmacology & therapeutics · 2022Review
- Investigation of cell signalings and therapeutic targets in PTPRK-RSPO3 fusion-positive colorectal cancer.PloS one · 2022Article
- The role of R-spondin proteins in cancer biology.Oncogene · 2021Review
- R-Spondins 2 and 3 Are Overexpressed in a Subset of Human Colon and Breast Cancers.DNA and cell biology · 2021Article
- Biomarker-guided therapy for colorectal cancer: strength in complexity.Nature reviews. Clinical oncology · 2020Review
- R-spondin 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent Manner.Hepatology communications · 2019Article
- Identification of a novel PRR15L-RSPO2 fusion transcript in a sigmoid colon cancer derived from superficially serrated adenoma.Virchows Archiv : an international journal of pathology · 2019Article
- Identification of RSPO2 Fusion Mutations and Target Therapy Using a Porcupine Inhibitor.Scientific reports · 2018Article
- Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer.British journal of cancer · 2018Article
- Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.Medical sciences (Basel, Switzerland) · 2018Review
- The role of APC in WNT pathway activation in serrated neoplasia.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2018Article
- R-spodin2 enhances canonical Wnt signaling to maintain the stemness of glioblastoma cells.Cancer cell international · 2018Article
- WNT signalling events near the cell membrane and their pharmacological targeting for the treatment of cancer.British journal of pharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
R-spondin (RSPO) gene fusions have recently been discovered in a subset of human colorectal cancer (CRC) in the U.S. population; however, whether the fusion is recurrent in CRC arising in patients from the other demographic areas and whether it is specific for CRC remain uncertain. In this study, we examined 75 primary CRCs and 121 primary lung cancers in the Japanese population for EIF3E-RSPO2 and PTPRK-RSPO3 fusion transcripts using RT-PCR and subsequent sequencing analyses. Although the expression of EIF3E-RSPO2 and PTPRK-RSPO3 was not detected in any of the lung carcinomas, RSPO fusions were detected in three (4%) of the 75 CRCs. Two CRCs contained EIF3E-RSPO2 fusion transcripts, and another CRC contained PTPRK-RSPO3 fusion transcripts. Interestingly, in one of the two EIF3E-RSPO2 fusion-positive CRCs, a novel fusion variant form of EIF3E-RSPO2 was identified: exon 1 of EIF3E was connected to exon 2 of RSPO2 by a 351-bp insertion. A quantitative RT-PCR analysis revealed that RSPO mRNA expression was upregulated in the three CRCs containing RSPO fusion transcripts, while it was downregulated in nearly all of the other CRCs. An immunohistochemical analysis and a mutational analysis revealed that the RSPO fusion-containing CRC had a CDX2 cell lineage, was positive for mismatch repair protein expression, and had the wild-type APC allele. Finally, the forced expression of RSPO fusion proteins were shown to endow colorectal cells with an increased growth ability. These results suggest that the expression of RSPO fusion transcripts is related to a subset of CRCs arising in the Japanese population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.